



ASX ANNOUNCEMENT

25 November 2019

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”) would like to advise that Mr Marjan Mikel has been appointed as the Company’s new Chief Executive Officer (CEO) and been appointed to the board of directors.

A highly experienced managing director and board member with a career spanning Australia, Europe and Japan, Marjan’s focus has been in the healthcare industry; from pharmaceuticals and information services and technology to medical devices and sleep disorder solutions. He founded and subsequently sold *Healthy Sleep Solutions* after developing it into a successful business, with in excess of \$70m in revenue, with Resmed Ltd as a joint venture/shareholder partner.

Currently, he is non-executive director of Memphasys Ltd, a publicly-listed bio-separations company, where he chairs the nomination and remuneration committee. He also acts as commercial advisor to Portt, a SaaS company, and is an industry research fellow at University of New South Wales Faculty of Engineering.

Marjan holds BSc (Hons), University of Sydney, Grad Dip Ed, Secondary Education, University of Sydney, MCom Masters of Commerce, University of New South Wales and MAICD, Business Administration, Management and Operations, AGSM, University of New South Wales.

Marjan will commence in his role as CEO on Monday 2 December 2019 and his appointment as a director of the Company will take effect immediately.

On behalf of the board of directors, I welcome Marjan to the Company and look forward to working with him to deliver the Company’s transition to commercialisation and the board’s long term strategy.

Nicholas Smedley
Executive Chairman

---End---

About Respi Limited

Respi's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.